Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Mohit Bansal
WF

Mohit Bansal

Wells Fargo
Wall Street Analyst
★★★☆☆
#1400
on 13Foresight · ranked by our own returns
57%
Success Rate
-0.9%
Average Return
77 of 134 calls profitable · -114.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 57% of Mohit Bansal's ratings turned a profit when each position was held for 1 year — averaging -0.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

135 Buy 59 Hold 0 Sell
Mohit's Stock Coverage 35 ratings · 2026-11-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
BMY
Bristol-Myers Squibb
 Oct 30, 2026 HOLD Buy
-2.2% avg upside
42 analysts
$60.00
3.88% Downside
 -0.3% ·
GILD
Gilead Sciences
 Oct 30, 2026 BUY Strong Buy
-27.3% avg upside
66 analysts
$190.00
11.33% Upside
 -0.8% ·
LLY
Eli Lilly & Co
 Oct 29, 2026 BUY Strong Buy
-16.7% avg upside
50 analysts
$1500.00
5.74% Upside
 +3.9% ·
BIIB
Biogen
 Oct 29, 2026 BUY Strong Buy
+6.6% avg upside
53 analysts
$310.00
22.31% Upside
 +1.5% ·
AMGN
Amgen
 Oct 27, 2026 HOLD Buy
-29.9% avg upside
57 analysts
$430.00
7.72% Downside
 +4.3% ·
MRK
Merck & Company
 Oct 26, 2026 BUY Strong Buy
-3.5% avg upside
44 analysts
$165.00
10.42% Upside
 +4.5% ·
BMRN
BioMarin Pharmaceutical
 Oct 20, 2026 BUY Strong Buy
+63.6% avg upside
52 analysts
$80.00
36.73% Upside
 +0.5% ·
VRTX
Vertex Pharmaceuticals
 Oct 15, 2026 BUY Strong Buy
-20.5% avg upside
62 analysts
$550.00
1.61% Downside
 +7.8% ·
VERA
Vera Therapeutics
 Oct 15, 2026 BUY Strong Buy
+114.1% avg upside
19 analysts
$70.00
125.95% Upside
 -1.7% ·
TVTX
Travere Therapeutics
 Oct 15, 2026 BUY Strong Buy
+15.5% avg upside
22 analysts
$80.00
58.80% Upside
 -5.5% ·
XNCR
Xencor
 Oct 15, 2026 BUY Strong Buy
+31.8% avg upside
29 analysts
$30.00
0.69% Upside
 +64.1% ·
ABBV
AbbVie
 Oct 15, 2026 BUY Strong Buy
-14.5% avg upside
47 analysts
$300.00
1.82% Upside
 +4.1% ·
REGN
Regeneron
 Oct 15, 2026 HOLD Strong Buy
-12.1% avg upside
60 analysts
$750.00
19.23% Downside
 +20.0% ·
NBIX
Neurocrine
 Oct 13, 2026 BUY Strong Buy
+27.3% avg upside
37 analysts
$200.00
36.81% Upside
 +25.4% ·
PFE
Pfizer
 Oct 12, 2026 HOLD Buy
+9.2% avg upside
46 analysts
$28.00
8.25% Downside
 +4.8% ·
SMMT
Summit Therapeutics
 Sep 28, 2026 BUY Buy
+83.4% avg upside
29 analysts
$30.00
87.19% Upside
 -4.4% ·
BNTX
BioNTech SE
 Sep 24, 2026 BUY Strong Buy
+48.9% avg upside
28 analysts
$140.00
58.75% Upside
 -14.6% ·
MIST
Milestone Pharmaceuticals
 Aug 13, 2026 BUY Strong Buy
+910.3% avg upside
8 analysts
$7.00
858.95% Upside
 -47.7% ·
MLYS
Mineralys Therapeutics, Inc.
 Aug 12, 2026 BUY Strong Buy
+150.9% avg upside
12 analysts
$55.00
202.61% Upside
 -45.2% ·
JAZZ
Jazz Pharmaceuticals
 Aug 10, 2026 BUY Strong Buy
+16.2% avg upside
36 analysts
$300.00
38.82% Upside
 -5.8% ·
HALO
Halozyme
 Aug 07, 2026 HOLD Strong Buy
-48.1% avg upside
20 analysts
$95.00
27.38% Downside
 -2.9% ·
IRWD
Ironwood Pharma
 May 05, 2026 HOLD Buy
+239.4% avg upside
23 analysts
$5.00
42.83% Upside
 +4.3% ·
WVE
Wave Life Sciences
 Apr 01, 2026 BUY Strong Buy
+443.6% avg upside
30 analysts
$13.00
262.20% Upside
 -49.9% ·
XENE
Xenon
 Aug 12, 2025 BUY Strong Buy
+53.0% avg upside
28 analysts
$47.00
25.60% Upside
 +81.3% ·
ARWR
Arrowhead Pharmaceuticals
 Jul 02, 2021 BUY Strong Buy
+26.6% avg upside
29 analysts
$95.00
58.56% Upside
 -43.0% ·
FTH
Faeth Therapeutics
 Jun 29, 2021 BUY Strong Buy
+160.3% avg upside
22 analysts
$14.00
25.19% Downside
 -75.4% ·
NMTRQ
9 Meters Biopharma
 Jun 04, 2021 BUY Buy
+3234374900.0% avg upside
11 analysts
$3.00
299999899.93% Upside
 · ·
PLRX
Pliant Therapeutics
 Apr 05, 2021 BUY Buy
+2494.5% avg upside
21 analysts
$52.00
5954.22% Upside
 · ·
IDYA
IDEAYA Biosciences
 Mar 24, 2021 BUY Strong Buy
+48.3% avg upside
31 analysts
$33.00
3.35% Upside
 -45.3% ·
CHRS
Coherus Biosciences
 Feb 25, 2021 BUY Buy
+1336.6% avg upside
19 analysts
$27.00
3152.58% Upside
 -23.1% ·
STTK
Shattuck Labs
 Jan 20, 2021 BUY Strong Buy
+276.2% avg upside
16 analysts
$75.00
1249.01% Upside
 -85.9% ·
AGIO
Agios Pharma
 Dec 23, 2020 BUY Strong Buy
+99.0% avg upside
30 analysts
$65.00
112.81% Upside
 -18.2% ·
CTMX
CytomX Therapeutics
 Sep 15, 2020 HOLD Strong Buy
+361.2% avg upside
21 analysts
$8.50
263.34% Upside
 -31.2% ·
ADAPY
Adaptimmune Therapeutics
 Apr 27, 2020 BUY Buy
+9923.9% avg upside
10 analysts
$5.00
21639.16% Upside
 · ·
AVTR
Avantor
 Jun 11, 2019 BUY Buy
+4.5% avg upside
27 analysts
$21.00
30.92% Upside
 -5.3% ·
🔒 30 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Mohit Bansal — Frequently Asked Questions
How accurate are Mohit Bansal's stock ratings?
Based on the calls 13Foresight could measure, about 57% of Mohit's ratings were profitable over a one-year hold, with an average return of -0.9% per rating, or -114.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Mohit ranked on 13Foresight?
Mohit Bansal is currently ranked #1400 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Mohit cover?
Mohit most recently has ratings on BMY, GILD, LLY, BIIB, AMGN, MRK, BMRN, VRTX, VERA, TVTX, XNCR, ABBV and 23 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.